Investigators evaluated remedy with Opdivo (nivolumab) plus Yervoy (ipilimumab) versus gemcitabine-carboplatin chemotherapy for beforehand untreated unresectable or metastatic urothelial carcinoma, in response to Dr. Guru Sonpavde.
Remaining outcomes from the cisplatin-ineligible affected person inhabitants evaluated within the CheckMate 901 trial have been shared on the 2025 ASCO Annual Assembly.
Notably, the Meals and Drug Administration (FDA) has authorised Opdivo together with chemotherapy for the first-line remedy of sufferers with unresectable or metastatic urothelial carcinoma in March 2024. This regulatory approval was generated by knowledge from the CheckMate 901 trial.
To additional focus on this subject, Sonpavde sat down for an interview with CURE dwell on web site on the assembly to debate how the outcomes of the CheckMate 901 trial could affect discussions round beginning immunotherapy versus customary chemotherapy within the remedy of sufferers with metastatic or unresectable urothelial most cancers who can not obtain cisplatin.
Sonpavde serves because the medical director of genitourinary oncology, and is an assistant director of the Scientific Analysis Unit and the Christopher Okay. Glanz Chair for Bladder Most cancers Analysis on the AdventHealth Most cancers Institute, situated in Orlando, Florida.
Trancript:
In the mean time … we actually can not institute Opdivo plus Yervoy, since it is not going to be authorised primarily based on these knowledge. In fact, being a adverse trial for the Opdivo plus Yervoy comparability, I believe it does present some momentum to the technique of mixed PD-1 and CTLA-4 remedy for a minimum of a subset of sufferers. Bear in mind, the PD-1/CTLA-4 technique can also be being checked out in metastatic illness.
We’re nonetheless awaiting a trial referred to as the NILE trial, which is platinum-based chemotherapy plus Imfinzi (durvalumab) and Imjudo (tremelimumab) for superior illness. That trial additionally has a (gemcitabine)-platinum plus Imfinzi comparability with (gemcitabine)-platinum as the usual. Additionally, we’ve got a probably much more thrilling neoadjuvant trial, which is Imfinzi and Imjudo plus Padcev (enfortumab vedotin-ejfv).
So, I believe there’s nonetheless some scope for a PD-1 plus CTLA-4 inhibition mixture coming into the clinic. We’ll have to attend and see what the outcomes of NILE and the neoadjuvant trial — that is the VOLGA trial — appear to be. Maybe there’s nonetheless some scope for that type of double immune checkpoint inhibitor mixture.
Transcript has been edited for readability and conciseness.
For extra information on most cancers updates, analysis and schooling, don’t overlook to subscribe to CURE®’s newsletters right here.
